Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

164.51 4.75 +2.97%

Follow NBIX

Alert me

Market cap: $16.2B
P/E: 23.6×
Fwd P/E: 20.6×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

	Older periods	Dec '25	Mar '26	Jun '26	Sep '26
P/E ratio Full definition →	+8 more quarters Free account	29.43	19.63	23.91	20.34
P/S ratio Full definition →		4.93	4.27	5.05	3.89
P/FCF ratio Full definition →		18.85	15.93	19.56	13.86
P/Operating CF Full definition →		36.33	90.81	124.80	36.46
P/B ratio Full definition →		4.34	3.89	4.61	3.72
Price to Tangible BV Full definition →		4.35	3.90	17.60	12.14
EV/Sales Full definition →		4.61	4.02	5.09	3.84
EV/EBITDA Full definition →		20.71	15.48	20.65	14.73
EV/Operating CF Full definition →		16.85	14.45	19.14	13.35
EV/FCF Full definition →		17.61	15.01	19.74	13.68
Quick Ratio Full definition →		2.92	2.51	1.46	1.72
Current Ratio Full definition →		3.39	2.93	1.87	2.04
Net Debt/EBITDA Full definition →		(7.20)	(6.56)	(2.17)	(1.94)
Debt/Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →		0.00	0.00	0.00	0.00
Asset Turnover Full definition →		0.69	0.72	0.73	0.75
Operating CF/Net income Full definition →		2.53	0.74	0.94	1.91
Capex/Depreciation Full definition →		(0.46)	(1.25)	(0.28)	(0.24)
Interest Coverage Full definition →		—	—	52.24	1,104.33
Research and Development Expense of Revenue Full definition →		32.05%	36.37%	34.07%	31.34%
Selling, General and Administrative Expense of Revenue Full definition →		37.47%	39.10%	45.85%	32.63%
Intangible Assets out of Total Assets Full definition →		0.00	0.00	0.51	0.48
Share Based Compensation of Revenue Full definition →		7.27%	7.02%	6.78%	4.84%
Graham Net Nets Full definition →		0.08	0.07	0.00	0.02
Graham Number Full definition →		59.55	71.55	76.16	77.39
Earnings Yield Full definition →		3.40%	5.09%	4.18%	4.92%
Free Cash Flow Yield Full definition →		5.31%	6.28%	5.11%	7.21%
Revenue per Share Full definition →		8.10	8.10	9.50	11.05
Operating CF per Share Full definition →		3.90	1.45	1.35	3.89
Capex per Share Full definition →		0.02	(0.09)	(0.08)	(0.11)
Free Cash Flow per Share Full definition →		3.93	1.36	1.27	3.78
Cash per Share Full definition →		14.88	13.10	3.86	7.26
Shareholders Equity per Share Full definition →		32.69	33.90	36.57	38.18
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		32.69	33.90	36.57	38.18
Free Cash Flow Full definition →		390.80	136.70	128.60	383.60
Working Capital Full definition →		1,779.30	1,604.40	763.00	1,023.60
Capital Expenditures Full definition →		2.40	(9.10)	(7.80)	(11.60)
Net Current Asset Value Full definition →		1,144.30	937.30	(28.00)	259.50
EV/EBIT Full definition →		21.30	15.82	21.62	16.04
Capex to Sales Full definition →		0.00	0.01	0.01	0.01
Price to Operating Income Full definition →		22.79	16.78	21.42	16.25
Other line items
Average Receivables Full definition →		582.95	642.05	741.35	842.65
Average Payables Full definition →		567.95	624.10	648.90	753.85
Average Inventory Full definition →		63.20	61.80	80.55	67.70
Average Assets Full definition →		4,175.10	4,296.95	4,624.45	4,946.55
Average Common Equity Full definition →		2,921.40	2,971.55	3,193.95	3,441.15

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026

Stockrow Weekly